Onconic Therapeutics said on the 2nd that last year's operating profit came to 12.6 billion won, up more than about 360% from a year earlier, turning to the black. Net profit for the same period was 13,724.22 million won.
Sales rose 259.8% on-year to 53.4 billion won. The company said the commercialization of its in-house developed new drug drove sharp increases in both sales and profit.
The results reflect revenue from a technology transfer milestone received from China partner Livzon following the success of phase 3 clinical trials in China and the filing for approval, along with sales growth of Korea's 37th new drug, the gastroesophageal reflux disease treatment "Ja Q Bo."
Ja Q Bo has been growing rapidly in the prescription market since its launch in Oct. 2024. According to UBIST out-of-hospital prescription data, Ja Q Bo's monthly prescription amount expanded from about 500 million won in Oct. 2024, the first month of launch, to about 6.6 billion won in Dec. 2025. It increased about 13 times in just over a year, establishing itself as a major product group in the gastroesophageal reflux disease treatment market.
Ja Q Bo has been growing rapidly in the prescription market since its launch in Oct. 2024. According to UBIST out-of-hospital prescription data, Ja Q Bo's monthly prescription amount expanded from about 500 million won in Oct. 2024, the first month of launch, to about 6.6 billion won in Dec. 2025, increasing about 13 times in just over a year and establishing itself as a major product group in the gastroesophageal reflux disease treatment market.
Onconic Therapeutics places significance on having built a business structure that reinvests revenue secured through the commercialization of Ja Q Bo into follow-up research and development (R&D) for new drugs. The company said the "Gilead-style virtuous R&D cycle in which revenue generated through new drug approvals is again connected to research and development funding" that it has emphasized is being realized in practice.
Based on this virtuous cycle, the company is accelerating development of its next-generation anticancer new drug pipeline. It is speeding up development by advancing "Nesuparib," a next-generation synthetic lethal dual-target anticancer therapy and its core pipeline, to phase 2 in four indications: pancreatic cancer, endometrial cancer, ovarian cancer, and gastric cancer. Nesuparib is being evaluated for its potential as a pan-tumor therapy that can be effective across multiple indications rather than confined to a specific cancer type.
A Onconic Therapeutics official said, "Building on the late-stage clinical, chemistry, manufacturing and controls (CMC), and regulatory experience of Ja Q Bo, which posted sales in the 50 billion won range in its first year on the market, we achieved the milestone of advancing our second new drug, Nesuparib, to phase 2 in four indications," adding, "This year, we plan to share Nesuparib's research results at major conferences in Korea and overseas to enhance its new drug value."